NEWS HIGHLIGHTSMedia Articles Related to Albenza (Albendazole)
albendazole-oral, Albenza
Source: MedicineNet Microsporidiosis Specialty [2005.03.02]
Title: albendazole-oral, Albenza
Category: Medications
Created: 3/2/2005
Last Editorial Review: 3/2/2005
Published Studies Related to Albenza (Albendazole)
Comparison of prednisolone plus albendazole with prednisolone alone for treatment of patients with eosinophilic meningitis. [2009.09]
Corticosteroid and the combination of corticosteroid and antihelminthic drug are safe and beneficial in relieving headaches in patients with eosinophilic meningitis. However, clinical trials comparing the efficacies of these regimens have never been reported.Prednisolone plus albendazole is no better than prednisolone alone for treatment of patients with eosinophilic meningitis.
Combination therapy with albendazole and praziquantel versus albendazole alone in children with seizures and single lesion neurocysticercosis: a randomized, placebo-controlled double blind trial. [2009.05]
CONCLUSIONS: A combination therapy for albendazole and praziquantel was statistically comparable to sole therapy with albendazole in eradicating lesions and preventing seizures.
A randomised, double-blind field trial of ivermectin alone and in combination with albendazole for the treatment of Mansonella perstans infections in Uganda. [2009.03]
The effect of a single dose of ivermectin alone (150-200microg/kg body weight) or in combination with albendazole (total of 400mg) in Mansonella perstans infection was assessed in a randomised, double-blind field trial in two endemic communities in Mukono and Luwero districts of Uganda... However, in general both treatment regimens in both communities had limited effect on microfilarial intensities, and only one individual (given combination treatment in Luwero) was mf-negative at 6 months and 12 months after treatment.
Patterns of soil-transmitted helminth infection and impact of four-monthly albendazole treatments in preschool children from semi-urban communities in Nigeria: a double-blind placebo-controlled randomised trial. [2009.02.19]
BACKGROUND: Children aged between one and five years are particularly vulnerable to disease caused by soil-transmitted helminths (STH). Periodic deworming has been shown to improve growth, micronutrient status (iron and vitamin A), and motor and language development in preschool children and justifies the inclusion of this age group in deworming programmes. Our objectives were to describe the prevalence and intensity of STH infection and to investigate the effectiveness of repeated four-monthly albendazole treatments on STH infection in children aged one to four years... CONCLUSION: Results from this study show that the moderate prevalence and low intensity of STH infection in these preschool children necessitates systematic treatment of the children in child health programmes.
Randomized controlled trial of albendazole in new onset epilepsy and MRI confirmed solitary cerebral cysticercal lesion: Effect on long-term seizure outcome. [2009.01.15]
No trials to date have focused on long-term seizure outcome in solitary cerebral cysticercal lesion (SCCL), which is believed to produce a relatively benign form of epilepsy. This is a prospective randomized controlled study to evaluate the effect of Albendazole on long-term seizure outcome in patients with MRI-confirmed solitary cerebral cysticercal lesion (SCCL)...
Clinical Trials Related to Albenza (Albendazole)
Effectiveness of Combined Albendazole and Ivermectin Treatment for Intestinal Worm Infections [Completed]
The aim of this study is to compare the efficacy and impact on growth of two drug treatments
against intestinal worms in schoolchildren from a rural area of Guatemala. According to the
World Bank, these intestinal worms are one of the top causes of childhood health problems in
many areas of the developing world (The World Bank, 1993). Infected children are more likely
to have inadequate nutrition due to the worm infections and are more likely to be shorter in
height and weigh less than children who are not infected. After collecting height and weight
information, we will split the children into two groups. One group will receive albendazole
and the other group will receive combined albendazole/ivermectin. Both groups will be
receiving albendazole, the current standard of care treatment. Ivermection is expected to
improve efficacy and nutritional benefit as well as add increased scope of treatment for the
worm Strongyloides, and ectoparasites such as scabies and head lice. Both treatment regimens
and the combination have been used millions of times in the developing world and are safe to
use. Co-administration of drugs would be a more efficient use of the opportunity to access
schoolchildren and provide deworming treatment.
Effect of Albendazole Dose on Treatment of Lymphatic Filariasis [Recruiting]
This study is conducted in Kerala, India. It will determine whether a new treatment regimen
of albendazole and diethylcarbamazine (DEC) for lymphatic filariasis can eliminate the
disease more quickly than the standard regimen. Lymphatic filariasis is caused by infection
with very small parasitic worms that are spread by mosquitoes. The disease can cause
swelling of the arms, legs, breast and scrotum and can progress to permanent swelling of the
legs or arms called elephantiasis. The study will see if a higher and more frequent dose of
albendazole is better at clearing filarial worms from the blood than the current treatment.
Healthy people between 18 and 55 years of age who are in good health and who are infected
with filarial worms may be eligible for this study.
Participants undergo the following procedures:
3-day hospital stay at the Filariasis Chemotherapy Unit of the T. D. Medical College Hospital
in Kerala, India
- Random assignment to receive either: 400 mg albendazole and DEC 300 mg given once a
year for 2 years (standard treatment); or 800 mg albendazole and DEC 300 mg given once
a year for 2 years; or 800 mg albendazole and DEC 300 mg given twice a year for 2
years.
- Urine pregnancy test for women of childbearing age .
- Ultrasound test to look for filarial worms.
- Treatment dose.
- Monitoring for symptoms
6-month 3-day hospital stay
- Medical history, physical examination and blood test.
- Repeat ultrasound in subjects whose first ultrasound detected adult worms.
- Treatment dose for subjects receiving medicine every 6 months.
- Urine pregnancy test for women of childbearing age.
1-year 3-day hospital stay
- Medical history, physical examination and blood test.
- Treatment dose.
- Repeat ultrasound in subjects whose first ultrasound detected adult worms.
- Urine pregnancy test for women of childbearing age.
18-month 3-day hospital stay
- Medical history, physical examination and blood test.
- Treatment dose for subjects receiving medicine every 6 months.
- Urine pregnancy test for women of childbearing age.
24-month 3-day hospital stay
- Medical history, physical examination and blood test.
- Treatment dose.
- Repeat ultrasound in subjects whose first ultrasound detected adult worms.
- Urine pregnancy test for women of childbearing age.
A Double-Blind, Placebo-Controlled Trial of Albendazole in HIV-Positive Patients With Intestinal Microsporidiosis [Completed]
To evaluate the efficacy (stool frequency) and safety (adverse experiences) of albendazole,
administered for 28 days, compared to placebo and for 62 days in open-label fashion, in
treating intestinal microsporidiosis in HIV-positive patients. To assess the effect of
albendazole on stool volume, weight gain, microsporidial counts in small bowel biopsies, and
on the relationship between microsporidial counts in stool and stool frequency and volume. To
correlate microsporidial counts with the clinical course of microsporidiosis.
Efficacy Albendazole and Levamisole Against STH on Unguja [Completed]
Field epidemiological studies undertaken during 2005 in four village locations in Northern
Unguja, Zanzibar examined mothers and their pre-school aged children for helminth
infections.
The prevalence of Ascaris lumbricoides was found to have remained relatively high despite
community-wide treatment with the mass administration of Albendazole (a WHO recommended
de-wormer) in coordination with community vitamin A supplementation.
One hypothesis for this is that the children and mothers had Ascaris infections more tolerant
to Albendazole that subsequently failed to clear. It is necessary to compare the present drug
efficiency of Albendazole (first-line de-wormer) with Levamisole (second-line de-wormer) on
STH infections such patients a case-control setting to shed light on the putative resistance
of local Ascaris/Trichuris to albendazole.
In so doing, this should clarify whether there is resistance developing towards Albendazole
and have possible implications for introducing combination therapies of Levamisole and
Albendazole for first line de-worming mothers and their children in the future.
Ivermectin Versus Albendazole for Chronic Strongyloidiasis [Recruiting]
A prospective controlled trial to compare the efficacy and safety of 7-day albendazole,
single dose ivermectin, and 2-single dose ivermectin in 72 patients with chronic
strongyloidiasis will be conducted at Siriraj Hospital, Bangkok, Thailand.
|
